natgillin/translations-raw huggingface dataset:
In SINGLE, 833 subjects were randomized and received at least one dose of either dolutegravir 50 mg once daily with fixed-dose abacavir-lamivudine (DTG + ABC/3TC) or fixed-dose efavirenz-tenofovir- emtricitabine (EFV/TDF/FTC).
V študiji SINGLE je bilo randomiziranih 833 oseb, ki so prejeli najmanj en odmerek dolutegravirja 50 mg enkrat na dan z ustaljenim odmerkom abakavir-lamivudin (DTG + ABC/3TC) ali ustaljenim odmerkom efavirenz-tenofovir-emetricitabin (EFV/TDF/FTC).
In single-dose crossover studies of Neoclarityn 5 mg orodispersible tablets with Neoclarityn 5 mg conventional tablets, the formulations were bioequivalent.
V navzkrižnih študijah primerjave enkratnega odmerka zdravil Neoclarityn 5 mg orodisperzibilne tablete z zdravilom Neoclarityn 5 mg tablete sta se ti dve formulaciji izkazali za bioekvivalentni.
In single-dose pharmacokinetic (PK) studies in young healthy subjects no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti součinkovanja memantina z gliburidom/metforminom ali donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance – active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti součinkovanja memantina z gliburidom/metforminom ali donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti interakcij memantina z gliburidom/metforminom ali donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti interakcij zdravilna učinkovina-zdravilna učinkovina memantina z gliburidom/metforminom ali donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance- active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti součinkovanja memantina z gliburidom/metforminom ali donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti interakcij memantina z gliburidom/metforminom ali donepezilom.
In single-dose pharmacokinetic (PK) studies in young healthy subjects, no relevant active substance-active substance interaction of memantine with glyburide/metformin or donepezil was observed.
V raziskavah farmakokinetike (PK) posameznega odmerka pri mladih zdravih osebah ni bilo opaziti interakcij zdravilna učinkovina-zdravilna učinkovina memantina z gliburidom/metforminom ali donepezilom.
In situations when the body is exposed to excessive physical and/or mental stress, patients may need additional substitution of immediate release hydrocortisone tablets especially in the afternoon/evening, see also section ‘Use in intercurrent illness’ where other ways of temporarily increasing the dose of hydrocortisone is described.
Kadar je telo izpostavljeno čezmernemu telesnemu in/ali psihičnemu naporu, bodo bolniki morda potrebovali dodatne nadomestne tablete hidrokortizona s takojšnjim sproščanjem, zlasti popoldne/zvečer; glejte tudi poglavje „Uporaba pri sočasni bolezni“, kjer so opisani drugi načini začasnega povečanja odmerka hidrokortizona
In situations where the venipuncture set provided cannot be used (e.g. when infusing into a peripheral or central line), a separate filter compatible with Kovaltry should be used.
V primerih, ko priloženega pribora za vensko punkcijo ni mogoče uporabiti (npr. pri infundiranju v periferni ali centralni kanal), je treba uporabiti ločen filter, ki je združljiv z zdravilom Kovaltry.
In situations where very high maternally derived antibody levels are expected, the vaccination protocol should be planned accordingly.
V primerih, ko se pričakuje povečana raven maternalnih protiteles, je treba načrtovati ustrezni protokol cepljenja.
In six Phase 2 and Phase 3 clinical trials, 1588 adult patients were treated with Zavicefta.
V šestih kliničnih preskušanjih 2. in 3. faze so z zdravilom Zavicefta zdravili 1588 odraslih bolnikov.
In sJIA and pJIA patients, ALT and AST levels should be monitored at the time of the second infusion and thereafter according to good clinical practice, see section 4.2.
Pri bolnikih s sJIA in pJIA je treba kontrolirati vrednosti ALT in AST pred drugo infuzijo, potem pa v skladu z dobro klinično prakso (glejte poglavje 4.2).
In sJIA and pJIA patients, neutrophils and platelets should be monitored at the time of second infusion and thereafter according to good clinical practice, see section 4.2.
Pri bolnikih s sJIA in pJIA je treba kontrolirati vrednosti nevtrofilcev in trombocitov pred drugo infuzijo, potem pa v skladu z dobro klinično prakso (glejte poglavje 4.2).
In sJIA patients, the central volume of distribution was 35 ml/kg and the peripheral volume of distribution was 60 ml/kg resulting in a volume of distribution at a steady state of 95 ml/kg.
Pri bolnikih s sJIA je bil centralni volumen distribucije 35 ml/kg, periferni volumen distribucije pa 60 ml/kg, kar je vodilo do volumna distribucije v stanju dinamičnega ravnovesja 95 ml/kg.
In SJIA, Ilaris has been studied in two main studies.
Pri sistemskem juvenilnem idiopatskem artritisu so zdravilo Ilaris poučevali v dveh glavnih študijah.
In SLE, some of these antibodies attack the body’s own cells and organs instead (autoantibodies).
Pri sistemskem eritematoznem lupusu pa ta protitelesa napadajo lastne celice in organe telesa (avtoprotitelesa).
In small children, accidental ingestion increases the risk for NSAID adverse effects.
Nenamerno zaužitje pri majhnih otrocih poveča tveganje za neželene učinke NSAID.
In small short-term clinical trials, approximately 12.5% of paediatric patients were observed to experience adverse reactions, the majority of which were local, non-serious ocular reactions such as conjunctival hyperaemia, eye irritation, eye discharge, and lacrimation increased (see also section 5.1).
V majhnih, kratkotrajnih kliničnih preskušanjih so opazili, da je imelo približno 12,5% pediatričnih bolnikov neželene učinke, ki so bili večinoma lokalne reakcije na očeh, ki niso opredeljene kot resne, na primer hiperemija veznice, draženje očesa, izcedek iz očesa in povečano solzenje (glejte tudi poglavje 5.1).
In smoking subjects with mild hepatic dysfunction administered olanzapine orally, mean elimination half-life (39.3 hr) was prolonged and clearance (18.0 l/hr) was reduced analogous to non-smoking healthy subjects (48.8 hr and 14.1 l/hr, respectively).
Po peroralnem dajanju olanzapina kadilcem z blagimi motnjami v delovanju jeter je bil srednji razpolovni čas izločanja (39,3 ure) podaljšan in očistek (18,0 l/h) zmanjšan tako kot pri zdravih nekadilcih (48,8 ure oziroma 14,1 l/h).
In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hours) of orally administered olanzapine was prolonged and clearance (18.0 l/hr) was reduced analogous to non- smoking healthy subjects (48.8 hours and 14.1 l/hr, respectively).
Pri kadilcih z blagimi motnjami v delovanju jeter je bil srednji razpolovni čas izločanja peroralno danega olanzapina (39,3 ure) podaljšan in očistek (18,0 l/h) zmanjšan tako kot pri zdravih nekadilcih (48,8 ur oziroma 14,1 l/h).
In smoking subjects with mild hepatic dysfunction, mean elimination half-life (39.3 hrs) was prolonged and clearance (18.0 l/hr) was reduced analogous to non-smoking healthy subjects (48.8 hrs and 14.1 l/hr, respectively).
Pri kadilcih z blagimi motnjami v delovanju jeter je bil srednji razpolovni čas izločanja (39,3 ure) podaljšan in očistek (18,0 l/h) zmanjšan tako kot pri zdravih nekadilcih (48,8 ure oziroma 14,1 l/h).
In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Riprazo HCT.
Pri bolnikih s primanjkljajem natrija in/ali hipovolemijo, na primer pri bolnikih, ki prejemajo visoke odmerke diuretikov, se lahko po uvedbi zdravljenja z zdravilom Riprazo HCT pojavi simptomatska hipotenzija.
In sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur after initiation of treatment with Sprimeo HCT.
Pri bolnikih s primanjkljajem natrija in/ali hipovolemijo, na primer pri bolnikih, ki prejemajo visoke odmerke diuretikov, se lahko po uvedbi zdravljenja z zdravilom Sprimeo HCT pojavi simptomatska hipotenzija.
In some age groups there are limited clinical study data (adults aged 60-79 years and children aged 10 to 17 years), very limited clinical study data (adults aged 80 years and older, children aged 6 months to 9 years) or no data (children aged less than 6 months) with an AS03-containing vaccine containing HA from H5N1 or from H1N1v manufactured using a different process as detailed in sections 4.4, 4.8 and 5.1.
Za nekatere starostne skupine je o cepivu z AS03 z vsebnostjo HA iz H5N1 ali iz H1N1v, pridobljenih z drugačnim postopkom, malo podatkov iz kliničnih študij (odrasli, stari od 60 do 79 let in otroci, stari od 10 do 17 let), zelo malo podatkov iz kliničnih študij (odrasli, stari 80 let ali več, otroci, stari od 6 mesecev do 9 let) ali jih sploh ni (otroci, mlajši od 6 mesecev), kot je podrobno opisano v poglavjih 4.4, 4.8 in 5.1.
In some case, these reactions have progressed to severe anaphylaxis, and they have occurred in close temporal association with development of factor IX inhibitors (see also 4.4).
V nekaterih primerih so te reakcije napredovale v hudo anafilaksijo, pojavljale pa so se v tesni časovni povezavi z razvojem inhibitorjev faktorja IX (glejte tudi poglavje 4.4).
In some cases as a consequence of anaemia, symptoms of cardiac ischaemia like chest pain or angina pectoris have been observed.
V nekaterih primerih so kot posledico anemije opazili simptome ishemije srca, kot so bolečine v prsnem košu ali angina pektoris.
In some cases as a result of stopping smoking, with or without CHAMPIX an adjustment of the dose of other medicines may be necessary.
V nekaterih primerih je zaradi prenehanja kajenja z zdravilom CHAMPIX ali brez njega morda potrebno prilagoditi odmerek drugih zdravil.
In some cases it can be possible that the source chondrocytes of the patient are not expandable or that the release criteria are not met, due to poor biopsy quality, patient characteristics, or manufacturing failure.
V nekaterih primerih je mogoče, da izvornih hondrocitov bolnika ni mogoče ekspandirati ali pa niso izpolnjena merila za sprostitev zaradi slabe kakovosti biopsije, profila bolnika ali proizvodne napake.
In some cases of suspected EM, patients tolerated the reintroduction of sunitinib therapy at a lower dose after resolution of the reaction; some of these patients also received concomitant treatment with corticosteroids or antihistamines.
V nekaterih primerih suma na EM so bolniki po izginotju reakcije prenašali ponovno uvedbo zdravljenja s sunitinibom v manjših odmerkih; nekateri od teh bolnikov so sočasno prejemali tudi kortikosteroide in antihistaminike.
In some cases where Renvela should be taken at the same time as another medicine.
V nekaterih primerih je treba zdravilo Renvela vzeti sočasno z drugim zdravilom.
In some cases where Sevelamer carbonate Zentiva should be taken at the same time as another medicine.
V nekaterih primerih je treba zdravilo Sevelamer carbonate Zentiva vzeti sočasno z drugim zdravilom.
In some cases you may have to stop taking one of the medicines.
V nekaterih primerih boste morda morali prenehati jemati katero od zdravil.
In some cases you may need a blood transfusion. unusual bruising or bleeding, sometimes severe.
V nekaterih primerih je potrebna transfuzija krvi; neobičajne (lahko hujše) podplutbe ali krvavitve.
In some cases your doctor may need to reduce your dose of Tarceva or interrupt treatment:
V nekaterih primerih bo zdravnik moral zmanjšati odmerek zdravila Tarceva ali prekiniti zdravljenje.
In some cases, a prior increase in body weight has been reported which may be a predisposing factor.
V nekaterih primerih so poročali o predhodnem zvečanju telesne mase kot o možnem dejavniku tveganja.
In some cases, during treatment, the following transitory clinical signs may be observed in dogs and cats:
V nekaterih primerih se lahko pri psih in mačkah med terapijo pojavijo naslednja prehodna klinična znamenja:
In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.
V nekaterih primerih, , zlasti pri mlajših bolnikih, bodo morda potrebni krajši razmiki med odmerki ali višji odmerki.
In some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.
V nekaterih primerih, zlasti pri mlajših bolnikih, pa bodo morda potrebni krajši presledki med odmerki ali pa večji odmerki.
In some cases, especially in younger patients, shorter dosing intervals or higher doses may be necessary.
V nekaterih primerih, zlasti pri mlajših bolnikih, bodo morda potrebni krajši razmiki med odmerki ali višji odmerki.
In some cases, exposure to concomitant medicinal products associated with aplastic anemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment.
V nekaterih primerih izpostavljenost sočasno jemanim zdravilom, ki jih povezujejo z aplastično anemijo, vključno s karbamazepinom, fenitoinom in sulfametoksazolom/trimetoprimom, otežuje oceno.
In some cases, exposure to concomitant medicinal products associated with aplastic anemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment.
V nekaterih primerih izpostavljenost sočasno jemanim zdravilom, ki jih povezujejo z aplastično anemijo, vključno s karbamezapinom, fenitoinom in sulfametoksazolom/trimetoprimom, otežuje oceno.
In some cases, fatalities have been reported (see section 4.8).
V nekaj primerih so poročali tudi o smrtnih primerih (glejte poglavje 4.8).
In some cases, if you are pregnant and need treatment for MCD, your doctor may advise that the benefit of taking SYLVANT for your health outweighs the possible risks to your unborn baby.
Če ste noseči in je potrebno zdravljenje multicentrične Castelmanove bolezni, vam v nekaterih primerih zdravnik lahko svetuje, da prednosti zdravljenja z zdravilom SYLVANT odtehtajo tveganja za vašega nerojenega otroka.
In some cases, it may be necessary to stop treatment with Temomedac.
V nekaterih primerih je treba zdravljenje z zdravilom Temomedac prekiniti.
In some cases, it may be necessary to stop treatment with Temozolomide SUN.
V nekaterih primerih je treba zdravljenje z zdravilom Temozolomid SUN končati.
In some cases, it might not be possible to go ahead with the planned treatment with Strimvelis.
V nekaterih primerih načrtovanega zdravljenja z zdravilom Strimvelis ni mogoče nadaljevati.
In some cases, myelodysplastic syndromes can lead to acute myeloid leukaemia (AML, a type of cancer affecting white blood cells).
V nekaterih primerih lahko mielodisplastični sindromi privedejo do akutne mieloidne levkemije (AML, vrste raka, ki prizadene bele krvne celice).
In some cases, ovarian cysts and these menstrual disorders have resolved upon discontinuation of Rapamune.
V nekaterih primerih so po prenehanju jemanja zdravila Rapamune ovarijske ciste in motnje menstrualnega ciklusa izginile.
In some cases, people with fever may develop low blood pressure, dizziness or other symptoms.
V nekaterih primerih lahko pri bolnikih z zvišano telesno temperaturo pride še do znižanja krvnega tlaka, omotice ali drugih simptomov.
In some cases, the patient may be unable to receive a scheduled infusion of Provenge.
V nekaterih primerih bolnik morda ne bo mogel prejeti načrtovane infuzije zdravila Provenge.
In some cases, the patient may be unable to receive Zalmoxis because of manufacturing issues.
V nekaterih primerih bolniki zdravila Zalmoxis morda ne bodo mogli prejeti zaradi težav pri izdelavi.
In some cases, these events did not resolve until the ibandronic acid was discontinued.
V nekaterih primerih ti dogodki niso prenehali, dokler niso difosfonatov ukinili.
In some cases, these reactions have progressed to severe anaphylaxis.
V nekaterih primerih lahko te reakcije napredujejo v hudo anafilaksijo.
In some cases, your doctor may recommend that you take iron supplements.
V nekaterih primerih lahko zdravnik lahko svetuje jemanje dodatkov železa.
In some cases, your doctor may recommend that you take iron supplements.
V nekaterih primerih vam lahko zdravnik lahko svetuje jemanje dodatkov železa.
In some cases, your Temomedac dose will be reduced or treatment stopped.
V nekaterih primerih bo odmerek zdravila Temomedac zmanjšal ali zdravljenje prekinil.
In some cases, your Temozolomide Teva dose will be reduced or treatment stopped.
Morda boste zaradi tega jemali manjši odmerek ali prenehali uporabljati zdravilo Temozolomide Teva.
In some clinical studies, Tritanrix HepB was used to reconstitute the lyophilised Hib vaccine (Hiberix); no interference in the immune response to any of the antigens was observed as compared to the responses observed following administration of the vaccines at separate sites (see section 6.2).
V nekaterih kliničnih študijah so Tritanrix HepB uporabili za rekonstitucijo liofiliziranega cepiva Hib (Hiberix); v primerjavi z odzivi po dajanju cepiv na različna mesta ni bil opažen medsebojni vpliv v imunskem odzivu na katerega od antigenov (glejte poglavje 6.2).
In some clinical studies, Tritanrix HepB was used to reconstitute the lyophilised Hib vaccine (Hiberix); no interference in the immune response to any of the antigens was observed as compared to the responses observed following administration of the vaccines at separate sites. (see section 6.2.).
V nekaterih kliničnih študijah so Tritanrix HepB uporabili za rekonstitucijo liofiliziranega cepiva Hib (Hiberix); v primerjavi z odzivi po dajanju cepiv na različna mesta ni bil opažen medsebojni vpliv v imunskem odzivu na katerega od antigenov (glejte poglavje 6.2).
In some incidences these pneumonia events were fatal (see section 4.8).
V nekaterih primerih je bil izid teh pljučnic smrt (glejte poglavje 4.8).
In some individuals a lowering of blood counts was noted.
Pri nekaterih posameznikih so opazili zmanjšanje števila krvnih celic.
In some of the conditioning treatments evaluated, relapse rates lower than 60% have also been reported at 5 years.
Pri nekaterih ocenjenih pripravljalnih zdravljenjih so poročali tudi o stopnjah ponovitve, nižjih od 60 % (za obdobje 5 let).
In some of the observed cases the patients were also receiving anti- coagulation therapy.
V nekaterih od opaženih primerov so bolniki prejemali tudi antikoagulantno zdravljenje.
In some of the observed cases the patients were also receiving anti-coagulation therapy.
V nekaterih od opaženih primerov so bolniki prejemali tudi antikoagulantno zdravljenje.
In some organisms that are resistant to erythromycin A due to inducible expression of the MLSB resistance determinant, the affinity of telithromycin for the 50S ribosomal subunit is more than 20- fold that of erythromycin A.
Pri nekaterih organizmih, ki so zaradi inducibilne ekspresije determinante odpornosti MLSB odporni proti eritromicinu A, je afiniteta telitromicina za ribosomsko podenoto 50S več kot 20-krat tolikšna kot afiniteta eritromicina A.
In some patients previously exposed to capecitabine, reports of palmar-plantar erythrodysaesthesiae have been reported as part of the continuing surveillance of Abraxane.
V okviru nadaljnjega spremljanja zdravila Abraxane so pri nekaterih bolnikih, ki so predhodno jemali kapecitabin, poročali o palmarno-plantarni eritrodisesteziji.
In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding.
Pri nekaterih bolnikih telo morda ne proizvaja dovolj krvnih celic, ki telesu pomagajo v boju proti okužbam ali pomagajo ustaviti krvavitve.
In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding.
Pri nekaterih bolnikih telo ne izdeluje dovolj krvnih celic za boj proti okužbam ali zaustavljanje krvavitev.
In some patients the body may fail to produce enough of the blood cells that help your body fight infections or help you to stop bleeding.
Pri nekaterih bolnikih telo ne ustvari dovolj krvnih celic, ki pomagajo pri premagovanju okužbe ali ustavitvi krvavitve.
In some patients the body may fail to produce enough of the blood cells that help your child's body fight infections or help him/her to stop bleeding.
Pri nekaterih bolnikih telo ne ustvari dovolj krvnih celic, ki pomagajo pri premagovanju okužbe ali ustavitvi krvavitve.
In some patients the eye pressure may increase for a short period directly after the injection.
Pri nekaterih bolnikih lahko pride do povišanja očesnega tlaka za kratek čas takoj po injiciranju.
In some patients treated with INCRELEX, an ultrasound examination of the heart (echocardiogram) showed an increased size of the heart muscle and abnormalities of heart valve function.
Pri nekaterih bolnikih, zdravljenih z zdravilom INCRELEX, je pregled srca z ultrazvokom (ehokardiogram) razkril povečanje srčne mišice in motnje delovanja srčnih zaklopk.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDS- om) in oportunističnimi okužbami v anamnezi (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku zdravljenja HIV.
In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDS- om) in oportunističnimi okužbami v zdravstveni zgodovini (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku zdravljenja HIV.
In some patients with advanced HIV infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started.
Pri nekaterih bolnikih z napredovalo okužbo s HIV (AIDS- om) in tistih, ki so imeli oportunistične okužbe v preteklosti (okužbe, ki se pojavijo pri ljudeh z oslabljenim imunskim sistemom), se lahko znaki in simptomi vnetja zaradi prejšnjih okužb pojavijo kmalu po začetku protiretrovirusnega zdravljenja.
In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Pri bolnikih z napredovalo okužbo z virusom HIV in z zgodovino opurtunistične infekcije se lahko znaki in simptomi vnetja prejšnje infekcije pojavijo kmalu po uvedbi zdravljenja zoper okužbo z virusom HIV.